Search This Blog

Wednesday, July 22, 2015

Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease (NYSE:LLY)

Results Presented at the Alzheimer's Association International Conference® 2015



Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.